$SUPV

Grupo Supervielle Reports 2Q26 Results

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV) reported 2Q26 results for the period ended June 30, 2026. It returned to profitability with attributable net income of AR$12.8bn and ROAE of 4.4%, or structural net income AR$41.9bn and structural ROAE 14.4% excluding extraordinary severance. NPL ratio fell to 5.5% and net cost of risk to 5.6%.

Original reporting
Published Aug 10, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Grupo Supervielle Reports 2Q26 Results — source image
Decision brief

The 30-second read

$SUPVBullishMed
01

Why it matters

The release combines quantified profitability improvement (NIM, efficiency), asset-quality improvement (NPL ratio, cost of risk), and capital strength (CET1 14.2%), framing a shift toward structurally lower cost to serve and higher adjusted returns.

02

Market read

For SUPV, the key tradable items are the sequential NIM expansion, improved NPL ratio and cost of risk, and the structural ROAE improvement tied to rightsizing, all reported in one earnings release.

03

What to watch

Loan book declined sequentially (-1.4%), and credit demand is described as subdued; traders may discount the recovery if growth re-acceleration does not materialize in 3Q26-4Q26.

Relevance 8/10Novelty 8/10Timing: after-hours results release for 2Q26 (Aug. 10, 2026)

Background

Supervielle is applying IFRS IAS 29 hyperinflation accounting and is executing an operating-model transformation with a headcount rightsizing plan launched in March 2026.

Company-level read

Ticker impact

$SUPVBullishMedium confidence
Context

Grupo Supervielle reported 2Q26 net income of AR$12.8B and expanded net interest margin to 20.3% from 17.7% sequentially.

Expected impact

Likely positive bias for SUPV as traders focus on margin expansion, decelerating provisions, and the structural ROAE improvement excluding severance.

Evidence & confidence

The article provides multiple quantified operating metrics (NIM, efficiency ratio, NPL ratio, cost of risk, CET1) plus a clear structural narrative tied to rightsizing and disinflation, which are actionable for earnings expectations even without explicit forward guidance.

Market effects

Argentine bank read-through: improving NPLs and funding-cost repricing support a broader risk-on view for regional financials if the trend holds.

Signals stabilization in Argentina’s credit cycle via lower cost of risk and disinflation, potentially improving sentiment toward local banks.

Limited direct global spillover, but could matter for EM financials exposure and ADR sentiment tied to Argentina macro normalization.

Counterpoint

The headline profitability recovery may be partly dependent on temporary margin dynamics from lagged asset repricing and one-off severance adjustments, so sustainability is uncertain.

Key entities

  • Grupo Supervielle S.A.

    Universal financial services group reporting 2Q26 results, including margin expansion, improved asset quality, and structural ROAE excluding severance.

  • Aerolíneas Argentinas

    Announced alliance referenced as strengthening the value proposition for Supervielle’s premium Identité segment.

  • Flash Argentina

    Agreement to exclusively provide secured financing for used-vehicle transactions on the marketplace starting 4Q26.

Related articles

$BBVAMed

Argentine country risk drops below 450 points, hitting 8

S&P upgraded Argentina’s sovereign credit rating from CCC+ to B- on Thursday, citing reduced economic vulnerability and improved external liquidity and debt-servicing capacity, including reserve accumulation and fiscal balance. Argentina’s country-risk index fell to 444 bps (below 450). Dollar bonds rose up to 3.3% and the S&P Merval gained 5.68% (7.3% in hard currency); ADRs climbed as much as 11.5%.

$NRXPLow

NRX Pharmaceuticals, Inc. (NRXP): Results of Operations and Financial Condition

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. nrxp20260817_8k.htm false 0001719406 0001719406 2026-08-17 2026-08-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

$HIVEMedAI 8/10

HIVE Digital Technologies Ltd. (HIVE): Results of Operations and Financial Condition

HIVE Digital Technologies Ltd. (HIVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Reports Q1 2027 Revenue of $79.1 Million; Contracted GPU Cloud ARR 1 Reaches Approximately $110 million This news relea

$AURXMed

Nuo Therapeutics, Inc. (AURX): Results of Operations and Financial Condition

Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_1005708.htm EXHIBIT 99 ex_1005708.htm Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attracti

$ETONHighAI 9/10

Eton Pharmaceuticals Swings To Q2 Profit; Revenue Jumps 99%

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% year over year, driven by HEMANGEOL sales. Net income was $11.6M, or $0.35/share, versus a net loss in Q2 2025. The company raised 2026 revenue guidance to over $145M and expects adjusted EBITDA margin of at least 35%.